BioViva Announces U.S. Patent for Klotho Gene Therapy Targeting Age-Related Cognitive Decline

Patent ExpiryKlotho Gene TherapyPositive

AI Analysis

Summary

BioViva USA announced the issuance of U.S. Patent No. 12,564,646 covering Klotho and hTERT gene therapy for age-related cognitive decline, strengthening the company's intellectual property position in aging-targeted therapeutics.

Outcome Details

U.S. Patent No. 12,564,646 issued covering the use of Klotho and hTERT gene therapy for age-related cognitive decline

Importance:4/10

Sentiment:

0.60

gene therapyagingcognitive declinepatent issuanceklotho

Related Companies

$KLTO

Read the original article

Published by PR Newswire Biotech on September 1, 2026 1:11 PM

Read Original